Implantable cardioverter defibrillators in heart failure with reduced ejection fraction after myocardial infarction: the need for contemporary evidence.
Chris P Gale, Gerhard Hindricks, Ramesh Nadarajah, Jan Tijssen, Serge Boveda, Jens Cosedis Nielsen, Jose Luis Merino, Radoslaw Lenarczyk, Milos Taborsky, Nikolaos Dagres
{"title":"Implantable cardioverter defibrillators in heart failure with reduced ejection fraction after myocardial infarction: the need for contemporary evidence.","authors":"Chris P Gale, Gerhard Hindricks, Ramesh Nadarajah, Jan Tijssen, Serge Boveda, Jens Cosedis Nielsen, Jose Luis Merino, Radoslaw Lenarczyk, Milos Taborsky, Nikolaos Dagres","doi":"10.1093/ehjqcco/qcaf018","DOIUrl":null,"url":null,"abstract":"<p><p>Sudden cardiac death is an important cause of death after myocardial infarction. Most of these episodes are considered the result of ventricular arrhythmia, with occurrence higher where myocardial infarction has been complicated by left ventricular systolic dysfunction. The landmark Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) and sudden cardiac death in heart failure (SCD-HeFT) trials, conducted around the turn of the millennium, established that treatment with implantable cardioverter defibrillators was superior to medical therapy for prevention of mortality in this context. Successive European Society of Cardiology guidelines provide a class I recommendation for the use of implantable cardioverter defibrillators for patients with persistent severe left ventricular systolic dysfunction after myocardial infarction and medicine optimization. This narrative review considers the historical randomized clinical trial evidence, the temporal trends in rate and cause of death in this patient population, as well as improvements in medical therapy, and why this necessitates a reappraisal of the benefit of implantable cardioverter defibrillators in the post-myocardial infarction population in contemporary clinical practice. Finally, details of the PROFID-EHRA trial are reported, which seeks to address this critical evidence gap.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":" ","pages":"816-824"},"PeriodicalIF":4.6000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Quality of Care and Clinical Outcomes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjqcco/qcaf018","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Sudden cardiac death is an important cause of death after myocardial infarction. Most of these episodes are considered the result of ventricular arrhythmia, with occurrence higher where myocardial infarction has been complicated by left ventricular systolic dysfunction. The landmark Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) and sudden cardiac death in heart failure (SCD-HeFT) trials, conducted around the turn of the millennium, established that treatment with implantable cardioverter defibrillators was superior to medical therapy for prevention of mortality in this context. Successive European Society of Cardiology guidelines provide a class I recommendation for the use of implantable cardioverter defibrillators for patients with persistent severe left ventricular systolic dysfunction after myocardial infarction and medicine optimization. This narrative review considers the historical randomized clinical trial evidence, the temporal trends in rate and cause of death in this patient population, as well as improvements in medical therapy, and why this necessitates a reappraisal of the benefit of implantable cardioverter defibrillators in the post-myocardial infarction population in contemporary clinical practice. Finally, details of the PROFID-EHRA trial are reported, which seeks to address this critical evidence gap.
期刊介绍:
European Heart Journal - Quality of Care & Clinical Outcomes is an English language, peer-reviewed journal dedicated to publishing cardiovascular outcomes research. It serves as an official journal of the European Society of Cardiology and maintains a close alliance with the European Heart Health Institute. The journal disseminates original research and topical reviews contributed by health scientists globally, with a focus on the quality of care and its impact on cardiovascular outcomes at the hospital, national, and international levels. It provides a platform for presenting the most outstanding cardiovascular outcomes research to influence cardiovascular public health policy on a global scale. Additionally, the journal aims to motivate young investigators and foster the growth of the outcomes research community.